BALAXI PHARMACEUTICALS share news, announcements and annual reports
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
BALAXI PHARMACEUTICALS LIMITED · Formerly Balaxi Ventures · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2015
Last close ₹19.15down ₹0.56 (2.84%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹19.71.
30 Oct: open ₹19.99, high ₹19.99, low ₹18.70
52-week range of traded prices to 30 Oct 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Next results date: the board meets on 12 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹106 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 43.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.42
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 21,37768.9% delivered
BALAXI PHARMACEUTICALS share news and announcements
466 announcements, routine notices left out, newest first. Page 10 of 10.
Aug 2016
25 Aug · Board meeting
Jul 2016
May 2016
Apr 2016
Feb 2016
13 Feb · Code of Conduct under SEBI(PIT) Reg., 2015
Jan 2016
Dec 2015
17 Dec · Legal
Clarification by The Anandam Rubber Company Limited Significant price movement has been observed in The Anandam Rubber Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. The Anandam Rubber Company Limitedhas vide its letter inter-alia stated, "There is no material change in the financials, Net worth or Business prospectus of the company. The company is not having any information/announcement (including impending announcement) which in our opinion having a bearing on price/volume behavior in the scrip."